# Multiple Cutaneous Adverse Reactions Secondary to Nivolumab Therapy in an Elderly Male

## TL;DR

An elderly man developed multiple skin reactions, including Sweet's syndrome, after nivolumab treatment for melanoma and showed partial improvement after adjusting the therapy.

## Contribution

This case highlights the occurrence of multiple cutaneous adverse reactions to nivolumab and their management in a single patient.

## Key findings

- The patient developed Sweet's syndrome, lichenoid eruption, and vitiligo-like depigmentation after nivolumab therapy.
- Discontinuation and treatment with dapsone and mometasone led to resolution of edematous plaques.
- Reducing the nivolumab dose prevented recurrence of Sweet's syndrome but not vitiligo-like depigmentation.

## Abstract

Nivolumab is a human IgG4, PD-1 inhibitor that is approved for the treatment of advanced melanoma. We hereby report a patient of metastatic melanoma who developed multiple cutaneous side effects, including Sweet's syndrome, lichenoid eruption, and vitiligo-like depigmentation after initiation of the nivolumab therapy. He first started developing vitiligo-like depigmentation over the lips, which appeared after five months. Later, he developed a mildly itchy lichenoid eruption over the thighs. The most recent and disabling one was the appearance of erythematous edematous painful plaques studded with pustules and vesicles with fever. The latter was diagnosed as Sweet's syndrome. Nivolumab was stopped, and the patient was started on oral dapsone 100 mg per day with topical mometasone 0.1% cream once a day application for these lesions. The patient had complete resolution of edematous plaques after four weeks of follow-up. Also, the subsequent dose of nivolumab was decreased by 20%, and this was not followed by the recurrence of Sweet's syndrome; however, vitiligo-like depigmentation persisted.